Soluble TNF Receptors Are Associated with Infarct Size and Ventricular Dysfunction in ST-Elevation Myocardial Infarction

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Nilsson, Lennart ^a,b   Szymanowski, Aleksander ^a,b   Swahn, Eva ^a,b   Jonasson, Lena ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN I; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

APOPTOSIS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TROPONIN I; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84873535599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055477     Document Type: Article

References (42)

1. Thatcher JL, Gilseth TA, Adlis S, (2003) Improved efficiency in acute myocardial infarction care through commitment to emergency department initiated primary PCI. J Invasive Cardiol 15: 693-698.
2. Keeley EC, Boura JA, Grines CL, (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361: 13-20.
3. Yellon DM, Hausenloy DJ, (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.
4. Piper HM, Meuter K, Schäfer C, (2003) Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75: S644-648.
5. Eltzschig HK, Eckle T, (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391-1401.
6. Olivetti G, Quaini F, Sala R, Lagrasta C, Corradi D, et al. (1996) Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28: 2005-2016.
7. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, et al. (1997) Apoptosis in human acute myocardial infarction. Circulation 95: 320-323.
8. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL, (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621-1628.
9. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, et al. (1997) Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141.
10. Nilsson L, Hallén J, Atar D, Jonasson L, Swahn E, (2012) Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98: 31-36.
11. Kandasamy AD, Chow AK, Ali MA, Schulz R, (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413-423.
12. Hengartner MO, (2000) The biochemistry of apoptosis. Nature 407: 770-776.
13. Weinlich R, Brunner T, Amarante-Mendes GP, (2010) Control of death receptor ligand activity by posttranslational modifications. Cell Mol Life Sci 67: 1631-1642.
14. Ohtsuka T, Hamada M, Sasaki O, Suzuki M, Hara Y, et al. (1999) Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis 10: 221-225.
15. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, et al. (2005) Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 111: 863-870.
16. Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, et al. (2005) Plasma levels of soluble tumor necrosis factor receptor type 1 during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 46: 2018-2021.
17. Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, et al. (2007) Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology 108: 117-123.
18. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, et al. (2009) Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 53: 720-729.
19. Frangogiannis NG, Smith CW, Entman ML, (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47.
20. Kakkar AK, Lefer DJ, (2004) Leukocyte and endothelial adhesion molecule studies in knock-out mice. Curr Opin Pharmacol 4: 154-158.
21. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, et al. (2004) Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789.
22. Bach TL, Barsigian C, Yaen CH, Martinez J, (1998) Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 273: 30719-30728.
23. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, et al. (2005) The fibrin-derived peptide Bbeta 15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 11: 298-304.
24. Roesner JP, Petzelbauer P, Koch A, Mersmann J, Zacharowski PA, et al. (2007) The fibrin-derived peptide Bbeta 15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med 35: 1730-1735.
25. Dall'Armellina E, Karamitsos TD, Neubauer S, Choudhury RP, (2010) CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol 7: 624-636.
26. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, et al. (2008) Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 94: 730-736.
27. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, et al. (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24: 28-66.
28. Lee Y, Gustafsson AB, (2009) Role of apoptosis in cardiovascular disease. Apoptosis 14: 536-548.
29. Bryant D, Becker L, Richardson J, Shelton J, Franco F, et al. (1998) Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97: 1375-1381.
30. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, et al. (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97: 5456-5461.
31. Burchfield JS, Dong JW, Sakata Y, Gao F, Tzeng HP, et al. (2010) The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail 3: 157-164.
32. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, et al. (2002) Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 34: 509-518.
33. Belosjorow S, Bolle I, Duschin A, Heusch G, Schulz R, (2003) TNF-alpha antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am J Physiol Heart Circ Physiol 284: H927-930.
34. Sugano M, Hata T, Tsuchida K, Suematsu N, Oyama J, et al. (2004) Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem 266: 127-132.
35. Lacerda L, Somers S, Opie LH, Lecour S, (2009) Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208.
36. Labruto F, Yang J, Vaage J, Valen G, (2005) Role of tumor necrosis factor alpha and its receptor I in preconditioning by hyperoxia. Basic Res Cardiol 100: 198-207.
37. Dawn B, Guo Y, Rezazadeh A, Wang OL, Stein AB, (2004) Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37: 51-61.
38. Beutler BA, Milsark IW, Cerami A, (1985) Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135: 3972-3977.
39. Bocci V, (1991) Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 21: 274-284.
40. Haudek SB, Taffet GE, Schneider MD, Mann DL, (2007) TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest 117: 2692-2701.
41. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, et al. (2001) Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104: 826-831.
42. Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, et al. (2004) Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci USA 101: 1297-1302.